Inventor · disambiguated record
John F. Seymour
Also filed as: SEYMOUR JOHN F
3 granted patents·6 pending applications·11 citations·filing 2020–2025
71Inventor score
Files withGENENTECH INC9
Top patents by PatentIndex Score
9 records- 0195US11110087B2Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitorGENENTECH INC·Filed 2021·Granted Sep 7, 2021·5 cites·29 claims
- 0294US11590128B2Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitorGENENTECH INC·Filed 2022·Granted Feb 28, 2023·3 cites·7 claims
- 0393US10993942B2Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitorGENENTECH INC·Filed 2020·Granted May 4, 2021·3 cites·30 claims
- 0487US2024000776A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 0587US2024108616A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 0684US2023226045A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 0781US2022265642A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2022·Application pending·0 cites
- 0878US2022211696A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2021·Application pending·0 cites
- 0976US2025152582A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John F. Seymour files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →